Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) have received a consensus rating of “Moderate Buy” from the twenty-six analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have given a hold rating and twenty-one have assigned a buy rating to the […] - 2025-04-18 05:44:49
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Needham & Company LLC in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $320.00 price target on the biopharmaceutical company’s stock. Needham & Company LLC’s price target would indicate a potential upside of […] - 2025-04-11 06:12:48
Corebridge Financial Inc. lessened its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 2.2% during the 4th quarter, HoldingsChannel reports. The fund owned 2,209 shares of the biopharmaceutical company’s stock after selling 50 shares during the quarter. Corebridge Financial Inc.’s holdings in Alnylam Pharmaceuticals were worth $520,000 at the end of […] - 2025-04-09 07:44:49
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price increased by Stifel Nicolaus from $300.00 to $345.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ price objective suggests a potential upside of 34.89% from the company’s previous close. A number […] - 2025-04-02 05:27:03
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price upped by research analysts at Scotiabank from $338.00 to $342.00 in a report issued on Monday,Benzinga reports. The firm presently has a “sector outperform” rating on the biopharmaceutical company’s stock. Scotiabank’s target price would indicate a potential upside of 33.72% from the company’s previous […] - 2025-04-02 05:26:50
Natixis Advisors LLC grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 4.5% during the 4th quarter, HoldingsChannel reports. The fund owned 10,453 shares of the biopharmaceutical company’s stock after acquiring an additional 451 shares during the quarter. Natixis Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $2,460,000 at the […] - 2025-03-24 08:44:53
Needham & Company LLC reiterated their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research note released on Friday,Benzinga reports. The brokerage currently has a $320.00 price target on the biopharmaceutical company’s stock. A number of other research firms have also recently issued reports on ALNY. William Blair reissued an […] - 2025-03-24 07:00:43
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective upped by Citigroup from $338.00 to $351.00 in a research note released on Friday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. ALNY has been the topic of several other research reports. William Blair reiterated an “outperform” rating on shares […] - 2025-03-24 06:24:53
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target increased by Canaccord Genuity Group from $385.00 to $390.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. Several other equities research analysts have also issued reports on the company. Bank of America raised their […] - 2025-03-24 05:48:46
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective lifted by Royal Bank of Canada from $310.00 to $330.00 in a research report released on Friday morning,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. ALNY has been the subject of several other reports. StockNews.com downgraded shares of Alnylam Pharmaceuticals […] - 2025-03-24 05:48:44
In trading on Friday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 0.7% on the day. Components of that ETF showing particular strength include shares of Alnylam Pharmaceuticals, up about 13.1% and shares of Cytokinetics, up about 7.8% on the day.
And unde - 2025-03-21 16:11:45
Atria Investments Inc increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 5.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,311 shares of the biopharmaceutical company’s stock after acquiring an additional 166 shares during the quarter. Atria Investments Inc’s […] - 2025-03-14 09:52:58
Proficio Capital Partners LLC lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 25,929.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 193,660 shares of the biopharmaceutical company’s stock after acquiring an additional 192,916 shares during the period. Alnylam Pharmaceuticals makes up approximately 0.6% of Proficio Capital Partners […] - 2025-03-14 09:05:23
Principal Financial Group Inc. lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 2.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,378 shares of the biopharmaceutical company’s stock after selling 230 shares during the quarter. Principal Financial Group Inc.’s holdings […] - 2025-03-06 10:01:07
New York Life Investment Management LLC increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 6.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,384 shares of the biopharmaceutical company’s stock after buying an additional 153 shares during the period. […] - 2025-03-05 10:04:47
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) have received a consensus rating of “Moderate Buy” from the twenty-five research firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have issued a buy […] - 2025-02-27 06:53:09
Sanctuary Advisors LLC boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 7.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,915 shares of the biopharmaceutical company’s stock after purchasing an additional 357 shares during the period. Sanctuary […] - 2025-02-26 08:50:51
Venturi Wealth Management LLC increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 6,200.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 252 shares of the biopharmaceutical company’s stock after acquiring an additional 248 shares during the […] - 2025-02-25 09:02:56
Vontobel Holding Ltd. lowered its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 75.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,804 shares of the biopharmaceutical company’s stock after selling 5,460 shares during the period. Vontobel Holding Ltd.’s […] - 2025-02-21 09:08:50
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) and Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings. Profitability This table compares Alnylam Pharmaceuticals and Mirum […] - 2025-02-21 07:10:51
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price raised by Canaccord Genuity Group from $384.00 to $385.00 in a report published on Tuesday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts have also commented on the company. Barclays increased their […] - 2025-02-19 07:56:18
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) was the recipient of a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 2,940,000 shares, a drop of 6.7% from the January 15th total of 3,150,000 shares. Based on an average daily volume of 708,000 shares, […] - 2025-02-17 10:22:50
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target upped by Morgan Stanley from $275.00 to $284.00 in a research note issued to investors on Friday,Benzinga reports. Morgan Stanley currently has an equal weight rating on the biopharmaceutical company’s stock. A number of other equities research analysts have also weighed in on the stock. […] - 2025-02-17 09:08:57
Royal Bank of Canada restated their outperform rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research note issued to investors on Tuesday,Benzinga reports. Royal Bank of Canada currently has a $300.00 price target on the biopharmaceutical company’s stock. A number of other brokerages have also weighed in on ALNY. Bank of […] - 2025-02-12 08:32:59
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $76.4 million dollar outflow -- that's a 1.2% decrease week over week ( - 2025-02-05 16:06:35
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received an average recommendation of “Moderate Buy” from the twenty-five brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have issued a buy rating on the company. […] - 2025-02-04 10:01:06
R Squared Ltd acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 140 shares of the biopharmaceutical company’s stock, valued at approximately $33,000. Other institutional investors and hedge funds have also recently modified […] - 2025-02-04 09:19:46
ALNY, HBT, APH, GNTY and OSUR have been added to the Zacks Rank #1 (Strong Buy) List on January 27, 2024. - 2025-01-27 10:56:00
ALNY institutional holdings
The following institutional investment holdings of ALNY have been identified
Date
ETF ISIN/Name
Num Shares
Book value
Fatal error: Uncaught mysqli_sql_exception: Column 'Currency_Code' in field list is ambiguous in /var/www/liquidata/show_aggregate_holdings.php:119
Stack trace:
#0 /var/www/liquidata/show_aggregate_holdings.php(119): mysqli->query()
#1 {main}
thrown in /var/www/liquidata/show_aggregate_holdings.php on line 119